Moderna Vaccine Creates Twice as Many Antibodies as Pfizer, Study Shows

Coronavirus: Modern vaccine generated more than double antibodies than Pfizer shot. Moderna Inc.’s Covid vaccine generated more than double the antibodies from a similar shot made by Pfizer Inc. and BioNTech SE in research that directly compared immune responses with inoculations.

A study of nearly 2,500 workers at a major hospital in Belgium found antibody levels among people who had not been infected with coronavirus before receiving two doses of the Moderna vaccine averaged 2,888 units per day. Milliliters, compared to 1,108 units / ml in a similar group that received two shots of the Pfizer shot.

The results, published Monday in a letter to the Journal of the American Medical Association, suggested that the differences could be explained by:

– larger amount of active ingredient in the Moderna vaccine – 100 micrograms versus 30 micrograms in Pfizer-BioNTech. Longer interval between doses of the Moderna vaccine – four weeks versus three weeks for Pfizer-BioNTech

Moderna’s vaccine was associated with a double risk reduction against breakthrough SARS-CoV-2 infections compared to Pfizers in a review of humans in the Mayo Clinic Health System in the United States from January to July. The results were reported in a separate study released prior to publication and peer review on 9 August.

The Moderna COVID‑19 vaccine (pINN: elasomeran), codenamed mRNA-1273 and sold under the brand name Spikevax, is a COVID-19 vaccine developed by Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA).

It is authorized for use in people aged twelve years and older in some jurisdictions and for people eighteen years and older in other jurisdictions to provide protection against COVID-19 which is caused by infection by the SARS-CoV-2 virus. It is designed to be administered as two or three 0.5 mL doses given by intramuscular injection at an interval of at least 28 days apart.

It is an RNA vaccine composed of nucleoside-modified mRNA (modRNA) encoding a spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles

By:

Source: Covid: Moderna Vaccine Creates Twice as Many Antibodies as Pfizer, Study Shows – Bloomberg

.

Related Contents:

Spikevax (previously COVID-19 Vaccine Moderna) EPAR”. European Medicines Agency

Moderna says preliminary trial data shows its coronavirus vaccine is more than 94% effective, shares soar

Coronavirus (COVID-19) Update: FDA Allows More Flexible Storage, Transportation Conditions for Pfizer-BioNTech COVID-19 Vaccine

Regulatory Decision Summary – COVID-19 Vaccine Moderna

Regulatory approval of Spikevax (formerly COVID-19 Vaccine Moderna)”. Medicines and Healthcare products Regulatory Agency

FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine

Moderna COVID-19 Vaccine Emergency Use Authorization

Early Data Show Moderna’s Coronavirus Vaccine Is 94.5% Effective

European Commission authorizes second safe and effective vaccine against COVID-19

Moderna aims for a billion COVID-19 shots a year with Lonza manufacturing tie-up

First data for Moderna Covid-19 vaccine show it spurs an immune response

Moderna Use Roche Antibody Test During Vaccine Trials

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Vaccination strategies for minimizing loss of life in Covid-19 in a Europe lacking vaccines

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.